FDA Approves New Potency Assay for Commercial Ryoncil
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Mesoblast Limited has received FDA approval for a new potency assay for its Ryoncil product, enhancing quality control measures. The T-cell Proliferation Inhibition BioAssay will be used to monitor the potency of commercial product lots. This approval marks a significant advancement in the manufacturing processes for Ryoncil, which is used to treat steroid-refractory acute graft versus host disease. The company aims to ensure the product remains consistent and clinically effective through this new assay.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
- Mesoblast Reports Substantial Revenue Growth to US$120M
- Major Milestone Treatment Completed in P3 Trial for CLBP
- Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
- Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Later from Mesoblast
- MSB Reports Increased Revenue and Improved Operating Spend
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast